In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 3, 2010, Pages 259-263

  Kahook, Malik Y ^a   Ammar, David A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALANCED SALT SOLUTION; BENZALKONIUM CHLORIDE; LATANOPROST; METHANOL; PROSTAGLANDIN DERIVATIVE; SAPONIN; SOFZIA; TAFLUPROST; TRAVATAN Z; TRAVOPROST; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; BENZALKONIUM; CLOPROSTENOL; PRESERVATIVE; PROSTAGLANDIN F;

ARTICLE; ASSAY; CELL SURVIVAL; CORNEA EPITHELIUM; DRUG FORMULATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; ANALOGS AND DERIVATIVES; CELL CULTURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; TOXICITY;

ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CELL SURVIVAL; CELLS, CULTURED; CLOPROSTENOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIUM, CORNEAL; HUMANS; IN VITRO TECHNIQUES; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F; PROSTAGLANDINS F, SYNTHETIC;

EID: 77954180771     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0003     Document Type: Article

References (30)

1. Le, A., Mukesh, B.N., McCarty, C.A., et al. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest. Ophthalmol. Vis. Sci. 44: 3783-3789, 2003.
2. Denis, P., Lafuma, A., Khoshnood, B., et al. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr. Med. Res. Opin. 23:601-608, 2007.
3. McCarey, B., and Edelhauser, H. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride. J. Ocul. Pharmacol. Ther. 23:445-451, 2007.
4. Martone, G., Frezzotti, P., Tosi, G.M., et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am. J. Ophthalmol. 147:725-735, 2009.
5. Baudouin, C., Liang, H., Hamard, P., et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 115:109-115, 2008.
6. Guenoun, J.M., Baudouin, C., Rat, P., et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci. 46:2444-2450, 2005.
7. Yee, R.W., Norcom, E.G., and Zhao, X.C. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv. Ther. 23:511-519, 2006.
8. Noecker, R.J., Herrygers, L.A., and Anwaruddin, R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 23:490-496, 2004.
9. Baudouin, C., Riancho, L., Warnet, J.M., et al. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest. Ophthalmol. Vis. Sci. 48:4123-4128, 2007.
10. Kahook, M.Y., and Noecker, R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv. Ther. 25:743-751, 2008.
11. Kahook, M.Y., and Noecker, R.J. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 27:339-343, 2008.
12. Liang, H., Baudouin, C., Pauly, A., et al. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br. J. Ophthalmol. 92:1275-1282, 2008.
13. Whitson, J.T., Cavanagh, H.D., Lakshman, N., et al. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv. Ther. 23:663-671, 2006.
14. Brasnu, E., Brignole-Baudouin, F., Riancho, L., et al. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr. Eye Res. 33:303-312, 2008.
15. Epstein, S.P., Ahdoot, M., Marcus, E., et al. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J. Ocul. Pharmacol. Ther. 25:113-119, 2009.
16. Ciancaglini, M., Carpineto, P., Agnifili, L., et al. An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes. Eur. J. Ophthalmol. 18:400-407, 2008.
17. Jaenen, N., Baudouin, C., Pouliquen, P., et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur. J. Ophthalmol. 17:341-349, 2007.
18. Katz, L.J. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J. Glaucoma 11:119-126, 2002.
19. Pisella, P.J., Debbasch, C., Hamard, P., et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest. Ophthalmol. Vis. Sci. 45:1360-1368, 2004.
20. Gipson, I.K. Distribution of mucins at the ocular surface. Exp. Eye Res. 78:379-388, 2004.
21. Noecker, R. Effects of common ophthalmic preservatives on ocular health. Adv. Ther. 18:205-215, 2001.
22. De Saint Jean, M., Brignole, F., Bringuier, A.F., et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 40:619-630, 1999.
23. Debbasch, C., Pisella, P.J., De Saint Jean, M., et al. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 42: 2525-2533, 2001.
24. Sosne, G., Albeiruti, A.R., Hollis, B., et al. Thymosin beta4 inhibits benzalkonium chloride-mediated apoptosis in corneal and conjunctival epithelial cells in vitro. Exp. Eye Res. 83:502-507, 2006.
25. Horsley, M.B., and Kahook, M.Y. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin. Ophthalmol. 3:291-295, 2009.
26. Hamacher, T., Airaksinen, J., Saarela, V., et al. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta. Ophthalmol. Suppl. (Oxf.) 242:14-19, 2008.
27. Lewis, R.A., Katz, G.J., Weiss, M.J., et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J. Glaucoma 16:98-103, 2007.
28. Thygesen, J., Aaen, K., Theodorsen, F., et al. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension. Acta. Ophthalmol. Scand. 78:37-44, 2000.
29. Fechtner, R. Prevalence of ocular surface disease symptoms in glaucoma patients on IOP-lowering medications. Presented at: American Glaucoma Society 2008 annual meeting; March 6-9, 2008; Washington DC, 3-6-0008.
30. Leung, E.W., Medeiros, F.A., and Weinreb, R.N. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma 17:350-355, 2008.